| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2015-03-24 | Ery-asp®/Graspa® (eryaspase - L-asparaginase loaded erythrocytes) | acute lymphoblastic leukemia | 3 | Erytech Pharma (France) | Cancer - Oncology |
| 2015-03-24 | SAR425899 | type 2 diabetes | 1 | Sanofi (France) | Metabolic diseases |
| 2015-03-23 | ALLOB® | degenerative lumbar disc disease | 2 | Bone Therapeutics (Belgium) | Bone diseases - Regenerative medicine |
| 2015-03-21 | Cosentyx® - secukinumab (AIN457) | psoriasis |
3 | Novartis (Switzerland) | Autoimmune diseases - Dermatological diseases |
| 2015-03-20 | Cosentyx® - secukinumab (AIN457) | psoriasis |
3b | Novartis (Switzerland) | Autoimmune diseases - Dermatological diseases |
| 2015-03-19 | BI-505 | smoldering multiple myeloma | 2 | BioInvent (Sweden) | Cancer - Oncology |
| 2015-03-19 | ValloVax™ | preclinical | Batu Biologics (USA - CA) | Cancer - Oncology | |
| 2015-03-19 | VH-N439 | therapeutic hypothermia |
preclinical | Vect-Horus (France) | Cardiovascular diseases - Cerebrovascular diseases |
| 2015-03-18 | CMD-003 - autologous Epstein-Barr virus specific T-cells | aggressive extranodal NK/T cell lymphoma (ENKTCL) |
2 | Cell Medica (UK) | Cancer - Oncology |
| 2015-03-18 | PT003 (combination of glycopyrronium and formoterol fumarate) | chronic obstructive pulmonary disease (COPD) |
3 | AstraZeneca (UK) | Inflammatory diseases - Pulmonary diseases - Respiratory diseases |
| 2015-03-18 | Remsima® (biosimilar infliximab) | inflammatory bowel disease, Crohn’s disease, ulcerative colitis | Celltrion Healthcare (South Korea) | Autoimmune diseases - Inflammatory diseases - Digestive diseases | |
| 2015-03-17 | bryostatin 1 | Alzheimer\'s disease | 1-2 | Neurotrope BioScience (USA - NJ) | Neurodegenerative diseases |
| 2015-03-16 | autologous CD34+ cells (NBS10) | ST Segment Elevation Myocardial Infarction |
2 | NeoStem (USA - NY) | Cardiovascular diseases |
| 2015-03-16 | BLU9931 | hepatocellular carcinoma |
preclinical | Blueprint Medicines (USA - MA) | Cancer - Oncology |
| 2015-03-15 | Repatha™ (evolocumab) | patients with high cholesterol | 3 | Amgen (USA - CA) | Cardiovascular diseases |
| 2015-03-15 | transthyretin (TTR)-mediated amyloidosis (ATTR amyloidosis) patients with familial amyloidotic cardiomyopathy (FAC) |
presentation of results at a meeting with members of the Association of Black Cardiologists (ABC) | Alnylam Pharmaceuticals (USA - MA) | Genetic diseases - Rare diseases | |
| 2015-03-14 | Repatha™ (evolocumab) | high cardiovascular risk and high cholesterol | 3 | Amgen (USA - CA) | Cardiovascular diseases |
| 2015-03-13 | BAX 817 | treatment of hemophilia A or B patients who have developed inhibitors |
3 | Baxter (USA - IL) | Hematological diseases - Genetic diseases - Rare diseases |
| 2015-03-11 | BL-9020 | type 1 diabetes |
preclinical | BiolineRx (Israel) | Metabolic diseases - Autoimmune diseases |
| 2015-03-10 | Metadoxine Extended Release (MDX), previously known as MG01CI (pyridoxol L-2-pyrrolidone-5-carboxylate) | Attention Deficit Hyperactivity Disorder (ADHD) | 2b | Alcobra (Israel) | CNS diseases - Mental diseases - Neurological diseases |
